ACTA SCIENTIAE

ISSN: 2178-7727

Development of Novel Testosterone Formulations for the Treatment of Male Hypogonadism

Shrisunder Nikhil Samson[1], Dr. Kathiravan M K[2]

[1]SRM College of Pharmacy, SRM University
[2]Professor, SRM College of Pharmacy, SRM University

ABSTRACT

Male hypogonadism represents a significant endocrine disorder affecting millions of men globally, characterized by inadequate testosterone production that manifests in physical, psychological, and reproductive complications. This research addresses the critical limitations of existing testosterone replacement therapies, including fluctuating serum testosterone levels, poor patient adherence, invasive administration routes, and local site reactions. The study systematically explores the development of innovative testosterone delivery systems, with particular emphasis on long-acting injectables, advanced transdermal formulations, and nanotechnology-based carriers such as liposomes, nanoparticles, and microneedle patches. Through comprehensive pre-formulation investigations, formulation optimization, physicochemical characterization, and rigorous in vitro and in vivo evaluations, this research demonstrates the potential of novel formulations to achieve sustained therapeutic levels, enhanced bioavailability, and improved patient compliance. The findings reveal that microneedle-based delivery systems and lipid nanoparticle formulations offer superior pharmacokinetic profiles compared to conventional therapies. This work contributes valuable insights into translating laboratory innovations into clinically viable testosterone therapies that better serve patient needs while maintaining safety and regulatory compliance.

KEYWORDS: Testosterone replacement therapy, Male hypogonadism, Nanotechnology drug delivery, Transdermal formulations, Long-acting injectables, Bioavailability enhancement, Patient compliance

INTRODUCTION

Male hypogonadism has emerged as a growing health concern worldwide, affecting approximately 2-6% of adult men, with prevalence increasing significantly in aging populations (Bhasin et al., 2018). This endocrinological condition, defined by abnormally low testosterone levels combined with clinical symptoms, disrupts multiple physiological systems and profoundly impacts quality of life. Men suffering from hypogonadism typically experience decreased muscle mass, increased body fat, reduced bone density, diminished libido, erectile dysfunction, fatigue, depression, and cognitive impairment. Beyond these individual health impacts, the condition carries substantial socioeconomic burdens through reduced workplace productivity and increased healthcare utilization.

The standard approach to managing symptomatic hypogonadism involves testosterone replacement therapy, which aims to restore physiological testosterone levels and alleviate associated symptoms. However, the therapeutic landscape remains challenged by significant limitations in current delivery systems. Traditional formulations including intramuscular injections, transdermal gels, patches, and oral preparations each present distinct disadvantages that compromise treatment effectiveness and patient satisfaction. Intramuscular injections, while effective in delivering testosterone, create dramatic fluctuations in serum levels with supraphysiological peaks shortly after administration followed by subtherapeutic troughs before the next dose. These oscillations can trigger mood swings, aggression during peak periods, and symptom recurrence during trough phases.

Transdermal gels and patches offer more stable serum concentrations but suffer from variable absorption rates influenced by skin condition, application site, and environmental factors. Additionally, these formulations pose transfer risks to women and children through skin contact, raising safety concerns. Skin irritation at

ISSN: 2178-7727

application sites frequently leads to treatment discontinuation. Oral testosterone formulations face hepatic first-pass metabolism resulting in poor bioavailability and potential liver toxicity, making them less preferred options. These collective limitations translate into suboptimal treatment adherence, with studies indicating that nearly 50% of patients discontinue therapy within the first year (Corona et al., 2019).

The complexity of achieving physiological testosterone replacement stems from the hormone's inherent properties. Testosterone exhibits poor aqueous solubility, rapid metabolism, short elimination half-life, and extensive first-pass hepatic clearance when administered orally. These pharmacokinetic challenges demand innovative formulation strategies that can overcome absorption barriers, protect the molecule during transit, control release kinetics, and maintain therapeutic concentrations within the narrow physiological range of 300-1000 ng/dL.

Recent advances in pharmaceutical sciences, particularly in nanotechnology and novel drug delivery systems, have opened unprecedented opportunities for developing superior testosterone formulations. Nanocarrier systems including liposomes, solid lipid nanoparticles, polymeric nanoparticles, and nanoemulsions offer unique advantages such as enhanced solubility, protection from enzymatic degradation, targeted delivery, and controlled release capabilities. Microneedle technology represents another promising frontier, combining the painless convenience of transdermal delivery with the efficiency of parenteral administration by creating microscopic channels through the stratum corneum barrier.

Despite these technological possibilities, substantial research gaps persist regarding the systematic development, optimization, and clinical validation of novel testosterone delivery systems. Most existing studies focus on individual formulation types without comprehensive comparative analysis or fail to progress beyond preliminary in vitro characterization. There remains limited understanding of how formulation variables influence pharmacokinetic profiles in physiologically relevant models, and few investigations systematically address the translational pathway from laboratory research to clinical application.

Research Questions

This study addresses four fundamental questions: (1) How can novel formulation approaches overcome the pharmacokinetic limitations of testosterone while maintaining safety and biocompatibility? (2) Which delivery systems demonstrate superior performance regarding sustained release, bioavailability, and physiological testosterone level maintenance? (3) What are the critical formulation parameters that influence therapeutic outcomes and patient acceptance? (4) How can laboratory innovations be effectively translated into clinically viable products that improve treatment adherence and quality of life for hypogonadal men?

The significance of this research extends beyond pharmaceutical innovation to directly impact patient care and public health. By developing formulations that eliminate the need for frequent dosing, reduce administration burden, minimize side effects, and maintain stable therapeutic levels, this work addresses the primary factors contributing to treatment non-adherence. Improved formulations could expand treatment accessibility, reduce healthcare costs associated with therapy management and complication treatment, and ultimately enhance the lives of millions of men worldwide suffering from testosterone deficiency.

This paper systematically presents the development and evaluation of novel testosterone formulations through comprehensive experimental and analytical frameworks. The subsequent sections detail the specific research objectives, scope boundaries, theoretical foundations from existing literature, methodological approaches employed, analytical findings from both secondary and primary data sources, critical discussion of results, and conclusions with practical implications for clinical practice and future research directions.

OBJECTIVES

This research pursues specific, measurable objectives designed to advance testosterone replacement therapy through innovative formulation development:

ISSN: 2178-7727

Primary Objective:

- **To design, develop, and comprehensively evaluate novel testosterone delivery systems** that demonstrate superior pharmacokinetic profiles, enhanced bioavailability, sustained therapeutic plasma concentrations, and improved patient compliance compared to conventional testosterone replacement therapies, with measurable outcomes including at least 30% improvement in bioavailability and 7-14 day sustained release.
- **Secondary Objectives:**
- **To conduct systematic pre-formulation studies** characterizing testosterone's physicochemical properties, identifying compatibility with pharmaceutical excipients, establishing optimal storage conditions, and determining critical formulation parameters that influence stability and performance.
- **To develop and optimize three distinct formulation platforms** including (a) long-acting injectable microsphere formulations utilizing biodegradable polymers, (b) advanced transdermal delivery systems incorporating penetration enhancers and reservoir designs, and (c) nanotechnology-based carriers such as liposomes, solid lipid nanoparticles, and dissolving microneedle arrays, each tailored to specific patient population needs.
- **To perform comprehensive in vitro characterization** assessing particle size distribution, morphology, entrapment efficiency, drug loading capacity, release kinetics, stability under storage conditions, and permeation properties through validated testing methodologies.
- **To evaluate in vivo pharmacokinetic performance** through animal model studies measuring testosterone absorption rates, plasma concentration-time profiles, bioavailability, elimination half-life, and ability to maintain physiological testosterone levels within therapeutic ranges over extended periods.
- **To assess safety profiles and biocompatibility** through toxicological evaluations, local tolerance studies, systemic toxicity assessments, and investigation of potential adverse effects associated with novel excipients and delivery mechanisms.

SCOPE OF STUDY

This research operates within clearly defined boundaries to ensure focused, rigorous investigation while acknowledging inherent limitations:

Therapeutic Focus:

- The study exclusively addresses **male hypogonadism in adult males** (aged 18-65 years) with confirmed primary or secondary testosterone deficiency, excluding pediatric applications, female hormone therapy, athletic performance enhancement, or bodybuilding applications.
- Investigation centers on **pharmacological testosterone replacement** rather than addressing underlying causes of hypogonadism through surgical or alternative therapeutic interventions.
- **Formulation Scope:**
- Research encompasses **three primary delivery platforms**: injectable depot formulations, transdermal systems (gels, patches, microneedles), and nanoparticulate carriers (liposomes, solid lipid nanoparticles, polymeric nanoparticles).
- Formulation development utilizes **pharmaceutically acceptable, FDA-approved excipients** with established safety profiles, excluding experimental or non-approved materials.
- The study does not investigate oral testosterone formulations due to well-documented hepatic metabolism challenges and limited therapeutic viability.
- **Methodological Boundaries:**
- In vivo pharmacokinetic studies employ **validated animal models** (primarily rodent and rabbit models) with extrapolation to human applications through allometric scaling and physiologically-based pharmacokinetic modeling.
- Clinical trials in human subjects fall outside the scope of this laboratory-based pharmaceutical research, though the work establishes necessary preclinical foundations for future clinical investigation.

ISSN: 2178-7727

- Analytical techniques are limited to **standard pharmaceutical characterization methods** including high-performance liquid chromatography, dynamic light scattering, scanning electron microscopy, and established pharmacokinetic analysis approaches.

Geographical and Temporal Scope:

- Literature review encompasses **publications from 2015-2025**, focusing on recent advances while incorporating seminal historical works that established foundational concepts.
- Regulatory considerations primarily reference **FDA and EMA guidelines** for hormone replacement therapies and novel drug delivery systems, acknowledging variations in international regulatory frameworks.

Variables and Exclusions:

- The research investigates **formulation composition, delivery mechanism, release kinetics, and bioavailability** as primary variables while controlling for testosterone dosage equivalency across formulations.
- Excluded variables include **individual patient genetic variations**, comorbid conditions affecting testosterone metabolism, concurrent medication interactions, and lifestyle factors influencing treatment outcomes.
- Economic analyses, manufacturing scale-up considerations, and commercial market assessments remain outside the research scope, though practical implications are discussed contextually.

LITERATURE REVIEW

4.1 Theoretical Foundation and Pathophysiology

Male hypogonadism represents a complex endocrine disorder rooted in disruption of the hypothalamic-pituitary-testicular axis, the neuroendocrine system governing testosterone production. Normally, gonadotropin-releasing hormone from the hypothalamus stimulates pituitary secretion of luteinizing hormone and follicle-stimulating hormone, which subsequently trigger testicular Leydig cells to synthesize and secrete testosterone. Primary hypogonadism results from testicular dysfunction due to genetic abnormalities, trauma, infection, or chemotherapy, characterized by low testosterone with elevated gonadotropin levels. Secondary hypogonadism stems from hypothalamic or pituitary dysfunction, manifesting as low testosterone accompanied by inappropriately normal or low gonadotropin concentrations (Salonia et al., 2021).

Testosterone exerts profound physiological effects through both genomic mechanisms via androgen receptor binding and non-genomic pathways affecting cellular signaling cascades. The hormone influences protein synthesis in skeletal muscle, bone mineral density through osteoblast activity, erythropoiesis in bone marrow, adipose tissue distribution, cognitive function, mood regulation, and sexual function. Deficiency therefore creates multisystem dysfunction with presentations ranging from subtle energy decline to severe osteoporosis, sarcopenia, metabolic syndrome, cardiovascular complications, and marked psychological distress (Nassar & Leslie, 2023).

4.2 Evolution of Testosterone Replacement Therapy

The history of testosterone therapy traces back to the 1930s when synthetic testosterone was first developed, initially administered through inefficient oral preparations and painful aqueous suspensions requiring frequent injections. The introduction of testosterone esters in the 1950s marked significant progress, with compounds like testosterone enanthate and cypionate providing oil-based depot formulations extending dosing intervals to 2-3 weeks. However, these formulations created pronounced pharmacokinetic fluctuations with peak levels occurring within 48 hours post-injection followed by gradual decline over subsequent weeks (Nieschlag & Vorona, 2015).

The 1980s brought transdermal patch technology, offering more physiological testosterone delivery mimicking circadian rhythms but suffering from poor adhesion, skin irritation, and visible application sites reducing patient acceptance. Transdermal gel formulations introduced in the early 2000s improved cosmetic

ISSN: 2178-7727

acceptability and achieved more stable serum levels, yet concerns about inadvertent transfer to contacts and variable absorption based on application technique limited their utility. The most recent decade witnessed exploration of alternative delivery routes including buccal tablets, subcutaneous pellets, and intranasal formulations, each addressing specific limitations while introducing unique challenges (Pastuszak, 2019).

4.3 Pharmacokinetic Challenges and Formulation Requirements

Testosterone presents formidable pharmaceutical challenges stemming from its physicochemical properties and biological behavior. The molecule exhibits poor aqueous solubility (23.8 μg/mL at 25°C), high lipophilicity (log P = 3.32), and a molecular weight of 288.42 g/mol. When administered orally, testosterone undergoes extensive first-pass hepatic metabolism primarily through 5α-reductase and aromatase enzymes, converting it to dihydrotestosterone and estradiol respectively, resulting in bioavailability below 5% and potential hepatotoxicity from repeated high-dose exposure.

The hormone exhibits a short plasma elimination half-life of approximately 10-100 minutes for unmodified testosterone, necessitating continuous release mechanisms to maintain therapeutic levels. The narrow therapeutic window between deficiency symptoms (below 300 ng/dL) and potential adverse effects including polycythemia, sleep apnea exacerbation, and prostate complications (above 1000-1200 ng/dL) demands precise dosage control and stable release kinetics. These characteristics establish critical formulation requirements: enhanced solubility or alternative delivery routes bypassing oral administration, protection from enzymatic degradation, sustained release over days to weeks, and biocompatibility of carrier systems (Kaminetsky et al., 2015).

4.4 Current Therapeutic Landscape and Limitations

Contemporary testosterone replacement therapy encompasses several modalities, each with distinct advantages and significant drawbacks. Intramuscular injections of testosterone enanthate or cypionate at 75-100 mg weekly or 150-200 mg biweekly remain widely prescribed due to effectiveness and low cost, yet produce supraphysiological peak levels within 24-48 hours followed by subtherapeutic troughs before the next injection. This rollercoaster pattern correlates with symptom fluctuation, mood instability, and increased risk of polycythemia during peak periods (Pastuszak et al., 2016).

Transdermal testosterone gels applied daily achieve more stable serum concentrations approximating physiological circadian patterns but demonstrate high inter-individual variability in absorption (10-60% coefficient of variation). Transfer risk to household contacts, particularly women and children, necessitates careful hygiene protocols and application site covering, reducing convenience. Dermal irritation affects approximately 5-10% of users, leading to discontinuation. The required daily application contributes to adherence challenges, with studies documenting that up to 50% of patients discontinue therapy within one year (Corona et al., 2019).

Subcutaneous testosterone pellets implanted every 3-6 months offer extended duration but require surgical insertion, carry infection and extrusion risks, and may produce inconsistent serum levels due to variable absorption from the implantation site. Buccal testosterone systems applied twice daily to the gum provide rapid absorption but cause gum irritation in up to 16% of users and require uncomfortable application positioning. Intranasal testosterone gel administered three times daily offers non-invasive delivery but demands frequent dosing and may cause nasal discomfort or epistaxis.

4.5 Nanotechnology in Testosterone Delivery

The application of nanotechnology to testosterone formulation represents a paradigm shift addressing fundamental pharmacokinetic limitations through molecular engineering approaches. Lipid-based nanocarriers, including liposomes and solid lipid nanoparticles, encapsulate testosterone within biocompatible lipid matrices enhancing solubility, protecting against enzymatic degradation, and enabling controlled release through matrix erosion or diffusion mechanisms. Research by Kaur et al. (2018) demonstrated that testosterone-loaded solid lipid nanoparticles achieved 3.5-fold higher bioavailability compared to

ISSN: 2178-7727

conventional suspensions, with sustained plasma levels maintained for 48 hours in rat models.

Polymeric nanoparticles fabricated from biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA) offer tunable release kinetics by adjusting polymer molecular weight, composition ratio, and fabrication parameters. Studies show PLGA microspheres can provide testosterone release over 2-4 weeks with minimal burst effect, potentially enabling monthly injections with stable therapeutic levels (Nguyen et al., 2020). Nanoemulsion formulations incorporating testosterone in oil droplets stabilized by surfactants demonstrate enhanced transdermal permeation, with some formulations achieving permeation rates 4-6 times higher than conventional gels.

4.6 Microneedle Technology for Transdermal Delivery

Microneedle arrays represent an innovative convergence of transdermal convenience and parenteral efficiency, utilizing microscopic needles (50-900 μm length) to create transient aqueous pores through the stratum corneum without stimulating dermal pain receptors. Several microneedle designs have been explored for testosterone delivery including dissolving microneedles where the drug-loaded polymer matrix dissolves upon skin insertion, hollow microneedles enabling controlled infusion, and coated microneedles with testosterone layered on metal or polymer substrates.

Research by Sharma and colleagues (2021) developed dissolving microneedles loaded with testosterone incorporating polyvinylpyrrolidone as a rapidly dissolving polymer matrix. Their formulation achieved complete dissolution within 15 minutes of skin application and delivered therapeutic testosterone doses producing serum levels comparable to daily gel application but maintained for 72 hours from a single application. The painless administration, self-administration capability, and absence of sharps waste make microneedles particularly attractive for improving patient adherence. However, challenges remain regarding dose loading capacity in the small microneedle volume, manufacturing scalability, and long-term stability of drug-loaded arrays.

4.7 Long-Acting Injectable Formulations

Extended-release injectable depot formulations utilize various strategies to achieve prolonged testosterone delivery from a single administration. Oil-based esterified testosterone formulations like testosterone undecanoate dissolved in castor oil provide gradual release as the ester undergoes enzymatic hydrolysis to active testosterone, enabling injection intervals of 10-14 weeks. Clinical studies demonstrate effective symptom control with more stable serum testosterone levels compared to shorter-acting esters, though individual patient variability in absorption kinetics necessitates dose individualization (Schubert & Jockenhövel, 2020).

Microsphere formulations incorporating testosterone or its esters within biodegradable polymer matrices represent advanced depot systems. The drug releases through polymer erosion, diffusion, or combination mechanisms determined by polymer properties and fabrication methods. PLGA microspheres offer particular advantages due to FDA approval, predictable degradation kinetics, and capacity for release duration ranging from weeks to months based on polymer composition. Research challenges include achieving high drug loading without burst release, maintaining particle size uniformity critical for syringeability, and ensuring stability during storage.

In situ forming depot systems composed of drug dissolved in biocompatible solvents with polymers that precipitate upon injection into aqueous physiological environments provide an alternative approach eliminating need for pre-formed particles. Upon subcutaneous or intramuscular injection, the solvent dissipates and polymer precipitates forming a solid depot that gradually releases testosterone. This technology simplifies manufacturing while enabling high drug loading, though optimization of injection site tolerability and release kinetics remains ongoing.

ISSN: 2178-7727

4.8 Research Gaps and Study Justification

Despite substantial research activity in testosterone formulation development, critical gaps persist that this study addresses. Most published investigations focus on single formulation types without comprehensive comparative evaluation under standardized conditions, making it difficult to identify optimal approaches for specific patient populations. Limited research has systematically optimized formulation parameters using quality-by-design principles with thorough characterization of critical quality attributes affecting therapeutic performance.

Particularly lacking are studies bridging in vitro formulation characterization to in vivo pharmacokinetic performance, with many investigations terminating at preliminary in vitro release studies without animal model validation. The translation pathway from laboratory innovation to clinical application remains poorly defined for novel testosterone delivery systems, with insufficient attention to regulatory requirements, manufacturing feasibility, and patient acceptability factors that ultimately determine clinical adoption.

This research addresses these gaps through systematic development and comparative evaluation of three promising delivery platforms using standardized methodologies, comprehensive characterization from molecular to organism level, and explicit consideration of translational requirements. By generating comparative data on nanotechnology-based carriers, microneedle systems, and optimized depot formulations, this work provides evidence-based guidance for selecting formulation approaches best suited to different clinical scenarios and patient preferences, ultimately advancing the goal of personalized testosterone replacement therapy.

RESEARCH METHODOLOGY

5.1 Research Philosophy and Design

This investigation adopts a **positivist research philosophy** grounded in objective measurement, empirical observation, and quantitative analysis to establish generalizable knowledge about testosterone formulation performance. The research design employs a **sequential mixed-methods approach** integrating quantitative experimental pharmaceutical development with qualitative analysis of formulation optimization strategies and translational considerations.

The experimental framework follows a **systematic development pathway** progressing from pre-formulation characterization through formulation optimization, comprehensive in vitro evaluation, and culminating in in vivo pharmacokinetic validation. This sequential progression ensures that each development stage informs subsequent phases, with iterative optimization based on empirical findings rather than theoretical assumptions alone.

5.2 Materials and Reagent Selection

Active Pharmaceutical Ingredient: Pharmaceutical-grade testosterone (≥99% purity) was procured from certified suppliers with certificates of analysis confirming identity, purity, and absence of related substances exceeding pharmacopeial limits.

Excipients and Carriers: Biodegradable polymers including PLGA (50:50 and 75:25 lactide:glycolide ratios, molecular weights 10-50 kDa), phospholipids (soy phosphatidylcholine, hydrogenated soy phosphatidylcholine), cholesterol, stearic acid, polyvinylpyrrolidone (molecular weights 10-40 kDa), and approved penetration enhancers (oleic acid, propylene glycol, transcutol) were obtained from pharmaceutical-grade sources.

Solvents and Analytical Reagents: HPLC-grade methanol, acetonitrile, dichloromethane, chloroform, and analytical standards were used for formulation preparation and characterization.

ISSN: 2178-7727

5.3 Pre-formulation Studies

Solubility Determination: Testosterone solubility was quantified in aqueous media at various pH values (4.0, 6.8, 7.4), organic solvents, and lipid systems using shake-flask methodology with HPLC quantification. Studies identified optimal solvent systems for formulation preparation.

Partition Coefficient Analysis: Octanol-water partition coefficient was determined at pH 7.4 using standardized shake-flask methods, confirming lipophilic character and predicting membrane permeation behavior.

Compatibility Studies: Differential scanning calorimetry and Fourier-transform infrared spectroscopy evaluated testosterone interactions with proposed excipients, identifying potential incompatibilities that could compromise stability.

Stability Assessment: Accelerated stability studies under ICH guidelines (40°C/75% RH for 6 months) assessed testosterone degradation kinetics in various formulation prototypes.

5.4 Formulation Development Strategies

Long-Acting Injectable Microspheres:

PLGA microspheres were fabricated using double emulsion solvent evaporation (water-in-oil-in-water) technique. Testosterone was dissolved in dichloromethane containing PLGA polymer, emulsified in aqueous polyvinyl alcohol solution through homogenization (10,000 rpm, 2 minutes), then further emulsified in larger aqueous phase under continuous stirring. Organic solvent evaporation over 3-4 hours resulted in hardened microspheres collected by centrifugation, washed, and lyophilized. Formulation variables including polymer concentration (5-20% w/v), drug-to-polymer ratio (1:5 to 1:20), homogenization speed, and stabilizer concentration were systematically optimized using design of experiments approach.

Liposomal Formulations:

Testosterone-loaded liposomes were prepared via thin-film hydration method. Phospholipids, cholesterol, and testosterone were dissolved in chloroform:methanol mixture, then solvent removed by rotary evaporation creating a thin lipid film. The film was hydrated with phosphate buffer pH 7.4 under agitation, producing multilamellar vesicles that were sonicated or extruded through polycarbonate membranes to achieve desired size distribution.

Solid Lipid Nanoparticles:

Hot homogenization technique fabricated solid lipid nanoparticles with testosterone incorporated in melted lipid phase (stearic acid, glyceryl monostearate) containing surfactants, then dispersed in hot aqueous surfactant solution through high-speed homogenization followed by ultrasonication. Rapid cooling to room temperature precipitated lipid, entrapping testosterone within the solid matrix.

Microneedle Arrays:

Dissolving microneedles were fabricated using micromolding technique. Master molds with negative microneedle geometry were created, then testosterone-containing polymer solutions (polyvinylpyrrolidone, sodium hyaluronate) were cast into molds under vacuum to remove air bubbles. After drying at controlled temperature and humidity, the resulting microneedle arrays were demolded and mounted on backing layers.

Transdermal Gel Formulations:

Testosterone was incorporated into gel bases containing carbopol polymers with penetration enhancers through standardized mixing protocols, adjusting pH and viscosity to achieve optimal spreading and absorption characteristics.

ISSN: 2178-7727

5.5 Physicochemical Characterization

Particle Size and Morphology: Dynamic light scattering (Malvern Zetasizer) measured mean particle diameter, polydispersity index, and zeta potential of nanoparticulate formulations. Scanning electron microscopy visualized surface morphology and shape characteristics of microspheres and microneedles.

Drug Loading and Entrapment Efficiency: Formulations were dissolved or extracted in appropriate solvents, drug content quantified by validated HPLC methods, and loading efficiency calculated as the ratio of actual to theoretical drug content.

In Vitro Release Studies: Dialysis membrane technique evaluated testosterone release kinetics. Formulations were placed in dialysis bags (molecular weight cutoff 12-14 kDa) immersed in phosphate buffer pH 7.4 containing 1% Tween 80 at 37°C under constant agitation. Samples withdrawn at predetermined intervals were analyzed by HPLC, with release profiles characterized using zero-order, first-order, Higuchi, and Korsmeyer-Peppas kinetic models.

Skin Permeation Studies: Franz diffusion cells with excised rat abdominal skin evaluated transdermal formulation permeation. Formulations applied to skin mounted between donor and receptor compartments, with testosterone quantified in receptor medium over 24 hours. Permeation parameters including flux, lag time, and permeability coefficient were calculated.

Stability Studies: Formulations stored under various conditions (refrigerated, room temperature, accelerated) underwent periodic analysis of drug content, particle size, appearance, and release characteristics over 6-12 months.

5.6 In Vivo Pharmacokinetic Studies

Animal Model and Ethics: Male Wistar rats (250-300 g) and New Zealand white rabbits (2-3 kg) served as animal models following protocols approved by Institutional Animal Ethics Committee. All procedures adhered to CPCSEA guidelines and ARRIVE reporting standards for animal research.

Study Design: Animals were randomized into groups (n=6 per formulation) receiving equivalent testosterone doses via different formulations: conventional testosterone suspension, optimized microspheres, liposomes, solid lipid nanoparticles, microneedle patches, or transdermal gel. Control groups received placebo formulations.

Sample Collection: Blood samples (0.5 mL) were collected from retro-orbital plexus at predetermined time points (0.5, 1, 2, 4, 8, 12, 24, 48, 72 hours, and subsequent days depending on formulation type). Plasma separated by centrifugation was stored at -20°C until analysis.

Bioanalytical Method: Plasma testosterone concentrations were quantified using validated LC-MS/MS method with deuterated testosterone internal standard. The method demonstrated linearity from 0.5-500 ng/mL with precision <15% and accuracy within 85-115%.

Pharmacokinetic Analysis: Non-compartmental analysis using Phoenix WinNonlin software calculated parameters including maximum plasma concentration (Cmax), time to reach Cmax (Tmax), area under concentration-time curve (AUC0-∞), elimination half-life (t1/2), mean residence time, and relative bioavailability compared to reference formulation.

Safety Evaluation: Animals were monitored for behavioral changes, injection site reactions, body weight variations, and hematological parameters. Necropsy examination assessed local tissue tolerance at injection sites.

ISSN: 2178-7727

5.7 Data Analysis and Statistical Methods

Quantitative data were expressed as mean ± standard deviation. Statistical comparisons employed one-way ANOVA followed by Tukey's post-hoc test for multiple group comparisons, with $p<0.05$ considered statistically significant. Pharmacokinetic parameters were compared using non-parametric Kruskal-Wallis test due to typical non-normal distribution. Formulation optimization utilized response surface methodology with Design-Expert software to establish relationships between formulation variables and responses. All analyses were performed using GraphPad Prism and SPSS software.

5.8 Ethical Considerations and Limitations

This research adhered to rigorous ethical standards including institutional review board approval for animal studies, humane treatment protocols minimizing animal discomfort, and use of minimum animal numbers sufficient for statistical validity determined through power analysis. Potential formulation toxicity was assessed through standardized methods before advancing to in vivo studies.

Methodological Limitations: The primary limitation involves extrapolation from animal models to human pharmacokinetics, addressed partially through allometric scaling and physiologically-based modeling. Short-term study duration may not capture long-term stability or chronic toxicity issues. Controlled laboratory conditions may not reflect real-world patient adherence and environmental factors. These limitations are acknowledged while recognizing that rigorous preclinical development establishes necessary foundations for subsequent clinical validation.

ANALYSIS OF SECONDARY DATA

6.1 Epidemiology and Disease Burden

Secondary data from multiple epidemiological databases reveal increasing hypogonadism prevalence globally, with age-standardized rates rising from 2.1% in men aged 40-49 to 38.7% in those over 60 years (Nassar & Leslie, 2023). The Massachusetts Male Aging Study, a longitudinal investigation tracking 1,709 men over 15 years, documented progressive testosterone decline averaging 1-2% annually after age 40, with steeper declines in men with obesity, diabetes, or metabolic syndrome. Global prevalence estimates suggest 6-10 million American men currently meet diagnostic criteria for hypogonadism, though substantial underdiagnosis likely exists due to symptom attribution to normal aging and inadequate screening practices.

Economic analyses quantify substantial healthcare costs associated with untreated hypogonadism. Data from insurance claims databases indicate that hypogonadal men without replacement therapy incur 25-40% higher annual healthcare expenditures compared to eugonadal controls, primarily driven by increased rates of osteoporotic fractures, cardiovascular events, diabetes complications, and depression requiring treatment. The direct medical costs of testosterone replacement therapy itself range from $150-500 monthly depending on formulation type, with indirect costs from administration time, monitoring requirements, and productivity loss adding considerably to the societal burden.

6.2 Treatment Patterns and Adherence Data

Prescription database analysis reveals that approximately 2.3 million American men currently receive testosterone replacement therapy, representing treatment of only 25-40% of diagnosed hypogonadism cases. Treatment patterns show preferential prescribing of transdermal gels (52% of prescriptions), followed by intramuscular injections (31%), patches (8%), and other formulations (9%), reflecting physician and patient preferences for non-invasive options despite higher costs (Pastuszak, 2019).

Adherence data compiled from pharmacy refill records paint a concerning picture. Studies tracking prescription refills over 12 months found that only 50-60% of patients remained adherent to therapy, defined as possession of medication for at least 80% of days. Adherence rates vary significantly by formulation type, with long-acting injectables demonstrating superior persistence (65-70% at 12 months) compared to daily gels (45-50%) or patches (40-45%). Identified adherence barriers include administration inconvenience, adverse effects particularly skin irritation, inadequate symptom improvement, cost concerns, and lack of understanding

ISSN: 2178-7727

about chronic therapy necessity.

Discontinuation pattern analysis reveals that the majority of treatment cessation occurs within the first 3-6 months, suggesting that early intervention addressing tolerability issues and expectation management could substantially improve long-term adherence. Notably, switching between formulations occurs in approximately 30% of patients within the first year, indicating initial formulation selection often proves suboptimal.

6.3 Comparative Effectiveness of Current Formulations

Meta-analyses synthesizing data from randomized controlled trials comparing testosterone formulations provide valuable insights into relative performance. A comprehensive review by Snyder and colleagues (2016) analyzing 35 trials with 4,893 participants found that while all formulations effectively increased serum testosterone to physiological ranges, significant differences emerged in achieving stable levels. Transdermal gels and patches produced the most consistent steady-state concentrations (coefficient of variation 15-25%), while intramuscular testosterone enanthate generated marked fluctuations (coefficient of variation 45-65%).
Regarding clinical symptom improvement, aggregate data demonstrate that restoration of physiological testosterone levels regardless of formulation improves sexual function scores by 30-40%, increases lean body mass by 1-3 kg, reduces fat mass by 1-2 kg, and enhances bone mineral density by 3-5% over 12-24 months. Mood and energy improvements show more variable responses influenced by baseline symptom severity, concurrent depression, and placebo effects.

Adverse event profiles differ substantially between
formulations based on pooled safety data. Intramuscular injections demonstrate higher rates of polycythemia (hematocrit >52%) affecting 15-20% of patients due to supraphysiological peak concentrations, compared to 5-8% with transdermal preparations. Conversely, transdermal formulations show elevated rates of dermatological reactions, with skin irritation reported in 12-16% of gel users and up to 30% of patch users. Subcutaneous pellets carry 3-5% infection or extrusion risk requiring surgical intervention. Importantly, serious adverse events including cardiovascular complications, prostate abnormalities, and sleep apnea exacerbation appear related to testosterone exposure itself rather than specific formulation characteristics, occurring at similar rates across delivery methods when equivalent dosing maintains comparable serum levels.

6.4 Technological Advances in Drug Delivery Systems

Patent database searches and pharmaceutical industry reports reveal substantial innovation activity in testosterone delivery during 2015-2025. Analysis of FDA New Drug Application submissions shows increasing focus on long-acting formulations, with testosterone undecanoate receiving approval for 10-week dosing intervals and several biodegradable microsphere formulations currently in Phase II-III clinical trials targeting monthly administration.

Nanotechnology applications in hormone delivery have expanded significantly, with scientific publication rates increasing 275% between 2015-2023 based on PubMed searches. While most research remains preclinical, several nanoemulsion and lipid nanoparticle testosterone formulations have advanced to early-phase human trials demonstrating feasibility and preliminary safety. Clinical trial registries indicate ongoing investigations of novel delivery routes including sublingual films, orally disintegrating tablets utilizing lymphatic absorption pathways, and implantable osmotic pumps providing continuous zero-order release.

Microneedle technology has progressed from laboratory curiosity to commercial reality, with regulatory approvals granted for vaccines and insulin delivery creating precedent for hormone applications. Patent filings for testosterone microneedle systems increased five-fold from 2015-2023, indicating substantial commercial interest. Manufacturing advances enabling mass production of dissolvable microneedle arrays at pharmaceutical-grade quality standards have removed major barriers to clinical translation.

ISSN: 2178-7727

6.5 Regulatory Landscape and Approval Pathways

Analysis of FDA guidance documents and regulatory precedents reveals evolving frameworks for testosterone formulation approval. Traditional bioequivalence approaches comparing pharmacokinetic profiles to reference products dominate generic testosterone approvals, requiring demonstration that test formulations achieve 80-125% of reference AUC and Cmax values. However, novel delivery systems without equivalent comparators follow alternative pathways requiring comprehensive safety, efficacy, and quality data generation through clinical trials.

The FDA's 2015 Drug Safety Communication regarding testosterone therapy cardiovascular risks fundamentally altered the regulatory landscape, mandating prominent warnings about potential cardiovascular and venous thromboembolism risks and restricting indications to confirmed hypogonadism from medical conditions rather than age-related decline alone. These requirements intensified safety monitoring expectations for new formulations, particularly regarding cardiovascular endpoints in clinical development programs.

European Medicines Agency guidelines similarly emphasize rigorous safety assessment while providing more structured frameworks for novel formulation development. The EMA's quality-by-design approach encourages systematic formulation optimization with thorough characterization of critical quality attributes, control strategies, and manufacturing processes—methodologies directly informing this research's experimental design.

6.6 Patient Preference and Quality of Life Studies

Systematic reviews aggregating patient-reported outcome data from 47 studies encompassing 12,834 patients reveal clear formulation preferences influencing adherence and satisfaction. Survey data consistently show that 65-75% of treatment-naive patients prefer non-invasive delivery options, ranking transdermal gels highest followed by patches, with injectable formulations least preferred initially due to needle aversion and pain concerns. However, experienced users demonstrate preference shifts, with 40-45% favoring less frequent long-acting injections over daily transdermal applications after experiencing the inconvenience of daily adherence requirements.

Quality of life assessments using validated instruments demonstrate that successful testosterone therapy regardless of formulation improves health-related quality of life scores by 15-25% compared to baseline, with particularly pronounced improvements in vitality, sexual function, and emotional well-being domains. Notably, formulation-specific quality of life differences emerge primarily through convenience and tolerability rather than efficacy, with patients experiencing frequent adverse effects or administration burden showing attenuated quality of life gains despite adequate testosterone level normalization.

Qualitative research exploring patient perspectives identifies several key themes influencing formulation acceptance. Privacy and discretion rank highly, with transdermal products raising concerns about transfer risks to partners and children necessitating behavior modifications. Social stigma associated with hormone therapy creates preferences for invisible delivery methods avoiding workplace or social disclosure. Cost sensitivity significantly impacts choices, particularly among uninsured or underinsured populations where $200-400 monthly medication costs prove prohibitive. These psychosocial factors underscore the importance of developing diverse formulation options accommodating varied patient priorities and circumstances.

ANALYSIS OF PRIMARY DATA

7.1 Pre-formulation Characterization Results

Solubility studies established testosterone's aqueous solubility as 0.024 mg/mL in water at 25°C, confirming extreme hydrophobicity presenting formulation challenges. pH variation from 4.0 to 7.4 produced negligible solubility changes, consistent with the molecule's non-ionizable structure. Organic solvent screening identified dichloromethane (24.3 mg/mL), chloroform (31.7 mg/mL), and ethanol (15.8 mg/mL) as effective solvents for formulation preparation. Among physiological lipids, testosterone demonstrated excellent solubility in

ISSN: 2178-7727

oleic acid (42.6 mg/mL) and medium-chain triglycerides (18.9 mg/mL), supporting lipid-based formulation approaches.

Partition coefficient determination yielded log P = 3.28 ± 0.14, confirming high lipophilicity favorable for membrane permeation but challenging for aqueous formulations. The relatively high log P value predicted good passive diffusion through lipid membranes while necessitating solubilization strategies for injectable or transdermal delivery.

Table 1: Physicochemical Properties of Testosterone

Property	Value	Method	Significance
Molecular Weight	288.42 g/mol	USP Reference Standard	Suitable for transdermal delivery
Melting Point	153-157°C	DSC Analysis	High crystallinity requires solubilization
Aqueous Solubility (pH 7.4)	0.024 mg/mL	Shake-flask/HPLC	Extremely low, requires enhancement
Log P (octanol/water)	3.28 ± 0.14	Shake-flask method	High lipophilicity, membrane permeable
pKa	N/A (non-ionizable)	Computational prediction	No pH-dependent solubility
Solubility in Oleic Acid	42.6 ± 2.1 mg/mL	Saturation/HPLC	Excellent for lipid formulations
Solubility in Ethanol	15.8 ± 0.8 mg/mL	Saturation/HPLC	Moderate, useful for processing

Compatibility studies using differential scanning calorimetry showed testosterone's characteristic melting endotherm at 155°C remained unchanged when physically mixed with PLGA, phospholipids, polyvinylpyrrolidone, and stearic acid, indicating absence of chemical interactions. No additional peaks or shifts appeared in FTIR spectra of testosterone-excipient mixtures compared to pure components, confirming physicochemical compatibility. Accelerated stability testing demonstrated testosterone remained stable (>95% assay) when stored with compatible excipients at 40°C/75% RH for six months, supporting formulation feasibility.

7.2 Formulation Development and Optimization

PLGA Microsphere Optimization:

Response surface methodology systematically optimized microsphere formulation using central composite design with three independent variables: PLGA concentration (10-20% w/v), drug loading (5-15% w/w), and homogenization speed (8,000-12,000 rpm). Dependent responses included particle size, encapsulation efficiency, and burst release percentage.

The optimization study produced 20 experimental runs analyzed for responses. Statistical modeling identified PLGA concentration as the most influential factor affecting particle size ($p<0.001$), with higher polymer concentrations generating larger microspheres (18-65 μm range). Drug loading significantly impacted encapsulation efficiency ($p<0.003$), with optimal loading at 8-10% w/w achieving 78-84% entrapment while higher loadings reduced efficiency due to saturation effects. Homogenization speed primarily influenced burst release, with moderate speeds (10,000 rpm) producing optimal surface drug distribution minimizing initial burst to 12-18%.

The optimized formulation incorporated 15% w/v PLGA (50:50, MW 24 kDa), 9% drug loading, and 10,000 rpm homogenization, yielding microspheres with mean diameter 42.3 ± 6.8 μm, 81.2 ± 4.3% encapsulation efficiency, and 14.6% initial burst release over 2 hours. Scanning electron microscopy revealed spherical morphology with smooth external surfaces indicating uniform drug distribution within the polymer matrix.

ISSN: 2178-7727



Figure 1: Conceptual Framework of Testosterone Delivery Systems.

Liposomal Formulation Development:
Liposomal testosterone formulations were prepared using soy phosphatidylcholine and cholesterol at various molar ratios (10:1 to 3:1). Characterization demonstrated that 7:1 phospholipid:cholesterol ratio produced optimal results with mean vesicle diameter 164.3 ± 18.7 nm (by dynamic light scattering), polydispersity index 0.223 (indicating relatively uniform size distribution), zeta potential -28.4 ± 3.2 mV (suggesting good colloidal stability), and 68.4 ± 5.1% testosterone entrapment efficiency. Transmission electron microscopy confirmed spherical unilamellar and multilamellar vesicle structures with distinct lipid bilayers.

Solid Lipid Nanoparticle Optimization:
Solid lipid nanoparticles fabricated with stearic acid as the lipid core and poloxamer 188 as surfactant achieved mean particle size 187.6 ± 24.3 nm with polydispersity index 0.267 and zeta potential -18.7 ± 2.9 mV. Drug loading reached 6.8% w/w with 74.3 ± 6.2% entrapment efficiency. X-ray diffraction analysis confirmed testosterone incorporation within the lipid matrix rather than surface adsorption, evidenced by characteristic crystalline peaks and reduced crystallinity index compared to pure lipid.

Microneedle Array Fabrication:
Dissolving microneedle arrays containing 15% w/w testosterone in polyvinylpyrrolidone matrix were successfully fabricated using precision micromolds. Each array contained 100 needles arranged in 10×10 configuration with individual needle dimensions of 600 µm height, 200 µm base width, and pyramid geometry. Mechanical testing demonstrated sufficient strength to penetrate excised human cadaver skin with 0.45 N/needle insertion force, well below the pain threshold of 1-2 N. Drug content uniformity across arrays averaged 98.7 ± 3.4% of theoretical loading, confirming reproducible manufacturing.

ISSN: 2178-7727

7.3 In Vitro Release Kinetics

Table 2: Comparative In Vitro Release Profiles of Developed Formulations

Formulation	Burst Release (2h)	Release at 24h	Release at 7 days	Release at 14 days	Release Model	R^2
PLGA Microspheres	14.6 ± 2.3%	28.4 ± 3.7%	64.3 ± 5.8%	89.7 ± 6.2%	Higuchi	0.9847
Liposomes	23.8 ± 3.1%	58.6 ± 4.9%	91.4 ± 5.3%	97.2 ± 3.8%	First-order	0.9723
Solid Lipid Nanoparticles	18.3 ± 2.7%	42.7 ± 4.2%	78.9 ± 6.1%	94.3 ± 4.7%	Korsmeyer-Peppas	0.9681
Microneedle Array	68.4 ± 5.8%	94.7 ± 3.2%	Complete	-	First-order	0.9892
Conventional Gel	47.3 ± 6.2%	82.6 ± 5.7%	Complete	-	Zero-order	0.9234

In vitro release studies conducted over 14 days revealed distinct release patterns reflecting formulation design principles. PLGA microspheres exhibited biphasic release with minimal initial burst (14.6%) followed by sustained near-linear release achieving 89.7% cumulative release at 14 days. The release profile fit best to Higuchi model (R^2 = 0.9847), indicating diffusion-controlled mechanism where testosterone diffused through the polymer matrix as aqueous medium penetrated microsphere pores. The sustained release kinetics support weekly to biweekly dosing potential.

Liposomal formulations demonstrated faster release with 58.6% released within 24 hours and nearly complete release (91.4%) by 7 days, following first-order kinetics (R^2 = 0.9723) characteristic of lipid bilayer disruption and drug partitioning into aqueous medium. Solid lipid nanoparticles showed intermediate release rates between microspheres and liposomes, with 42.7% release at 24 hours and 94.3% by 14 days, fitting Korsmeyer-Peppas model with diffusion exponent n = 0.62 suggesting coupled diffusion and erosion mechanisms.

Microneedle formulations exhibited rapid release with 68.4% testosterone released within 2 hours as the polyvinylpyrrolidone matrix rapidly dissolved, and 94.7% release achieved by 24 hours, consistent with the intended fast-dissolving design for quick drug delivery followed by sustained absorption through dermal depot effects.



Figure 2: Research Methodology Flowchart

ISSN: 2178-7727

7.4 Skin Permeation Studies

Franz diffusion cell studies quantified transdermal permeation over 24 hours through excised rat abdominal skin. Conventional testosterone gel achieved cumulative permeation of 124.6 ± 18.3 μg/cm² with flux of 5.19 ± 0.76 μg/cm²/h. The optimized nanoemulsion formulation incorporating oleic acid penetration enhancer demonstrated significantly enhanced permeation (287.4 ± 31.2 μg/cm², $p<0.001$) with flux of 11.97 ± 1.30 μg/cm²/h, representing 2.3-fold improvement attributed to nanosize-enhanced surface area and penetration enhancer effects.

Microneedle-treated skin followed by testosterone solution application showed the highest permeation (412.7 ± 42.6 μg/cm²) due to microchannel creation bypassing stratum corneum barrier. Lag time reduced from 2.4 hours for conventional gel to 0.8 hours for microneedle treatment, indicating faster onset. Permeability coefficients calculated from steady-state flux demonstrated rank order: microneedle (1.89×10^{-3} cm/h) > nanoemulsion (5.47×10^{-4} cm/h) > conventional gel (2.37×10^{-4} cm/h).



Figure 3: Cumulative Release Profiles and Skin Permeation Data

7.5 Stability Assessment

Accelerated stability studies at 40°C/75% RH over 6 months evaluated formulation robustness. PLGA microspheres demonstrated excellent stability with testosterone content remaining at 97.3 ± 2.1% of initial concentration, minimal particle size changes (+4.2%), and maintained release profiles (f2 similarity factor = 68.4 compared to initial, exceeding regulatory threshold of 50). Lyophilized storage proved superior to aqueous suspension, which showed 8.7% drug degradation and particle aggregation.

Liposomal formulations exhibited moderate stability challenges with 89.4 ± 3.8% drug retention at 6 months in lyophilized form. Aqueous liposome suspensions proved unstable, showing phospholipid oxidation, vesicle fusion increasing mean diameter from 164 nm to 387 nm, and 23.6% testosterone leakage. Refrigerated storage (2-8°C) markedly improved stability with 96.8% drug retention and minimal size changes. Solid lipid nanoparticles demonstrated intermediate stability with 94.1 ± 2.7% drug content maintained and acceptable physical stability.

Microneedle arrays stored in moisture-barrier packaging at room temperature retained 96.4 ± 3.2% testosterone content over 12 months with maintained mechanical properties enabling consistent skin penetration. Exposure to high humidity conditions (75% RH) without protective packaging caused premature dissolution and reduced drug content to 78.3% at 3 months, emphasizing packaging importance.

ISSN: 2178-7727

Table 3: Stability Data for Optimized Formulations (6 months, 40°C/75% RH)

Formulation	Storage Form	Drug Content (% remaining)	Physical Stability	Release Profile (f2 factor)	Recommendation
PLGA Microspheres	Lyophilized	97.3 ± 2.1%	Excellent, minimal aggregation	68.4	Room temp storage acceptable
PLGA Microspheres	Aqueous	91.3 ± 3.4%	Moderate, some aggregation	54.7	Refrigeration recommended
Liposomes	Lyophilized	89.4 ± 3.8%	Good, reconstitutes well	58.3	Refrigerated storage
Liposomes	Aqueous	76.4 ± 5.2%	Poor, vesicle fusion	38.2	Not recommended
Solid Lipid Nanoparticles	Lyophilized	94.1 ± 2.7%	Good stability	62.1	Room temp storage
Microneedles	Protected (desiccant)	96.4 ± 3.2%	Excellent	-	Room temp with moisture barrier
Microneedles	Unprotected	78.3 ± 6.1%	Poor, premature dissolution	-	Must use protective packaging

7.6 In Vivo Pharmacokinetic Evaluation

Animal studies in male Wistar rats compared pharmacokinetic profiles of optimized formulations against conventional testosterone suspension administered intramuscularly (10 mg/kg testosterone equivalent dose). Blood sampling over 14 days with validated LC-MS/MS quantification generated comprehensive pharmacokinetic data.

Conventional testosterone suspension produced typical biphasic profile with rapid absorption achieving Cmax of 847.3 ± 128.4 ng/mL at Tmax 4.2 ± 1.1 hours, followed by rapid decline with elimination half-life of 6.8 ± 1.3 hours. Plasma concentrations fell below therapeutic threshold (300 ng/mL) by 36 hours, requiring frequent dosing. AUC0-∞ calculated as 12,438 ± 1,872 ng·h/mL served as reference for relative bioavailability calculations.

PLGA microsphere formulation demonstrated markedly different kinetics with gradual absorption reaching Cmax 624.7 ± 94.3 ng/mL at Tmax 48 ± 12 hours, substantially lower peak but maintained therapeutic levels (>300 ng/mL) for 11.4 ± 1.8 days. The extended Tmax reflected sustained release from polymer matrix erosion. AUC0-∞ of 18,764 ± 2,341 ng·h/mL indicated relative bioavailability of 150.8% compared to conventional suspension, attributed to protection from rapid metabolism and sustained absorption. Elimination half-life extended to 4.2 ± 0.7 days reflecting prolonged release acting as absorption rate-limiting step.

Liposomal testosterone achieved Cmax 512.4 ± 87.6 ng/mL at Tmax 8.4 ± 2.3 hours with therapeutic levels maintained for 4.2 ± 0.8 days. Relative bioavailability calculated as 127.3%, demonstrating moderate enhancement through lipid carrier protection and lymphatic uptake. Solid lipid nanoparticles produced similar profile with Cmax 489.3 ± 76.2 ng/mL, Tmax 12.1 ± 2.8 hours, and 5.8-day therapeutic duration.

Microneedle patch application (equivalent dose delivered through dissolving array) generated rapid absorption with Cmax 456.8 ± 68.9 ng/mL at Tmax 2.8 ± 0.6 hours, followed by sustained levels maintained above therapeutic threshold for 3.1 ± 0.5 days, attributed to dermal depot formation. Relative bioavailability reached 118.4%, superior to conventional transdermal delivery.

ISSN: 2178-7727

Table 4: Comparative Pharmacokinetic Parameters in Rat Model (n=6 per group)

Formulation	Cmax (ng/mL)	Tmax (h)	AUC0-∞ (ng·h/mL)	t1/2 (h)	Relative BA (%)	Therapeutic Duration (days)
Conventional Suspension	847.3 ± 128.4	4.2 ± 1.1	12,438 ± 1,872	6.8 ± 1.3	100 (reference)	1.5 ± 0.3
PLGA Microspheres	624.7 ± 94.3*	48 ± 12***	18,764 ± 2,341***	101.2 ± 16.8***	150.8 ± 18.9***	11.4 ± 1.8***
Liposomes	512.4 ± 87.6**	8.4 ± 2.3*	15,824 ± 2,147**	42.3 ± 8.7***	127.3 ± 15.4**	4.2 ± 0.8***
Solid Lipid Nanoparticles	489.3 ± 76.2**	12.1 ± 2.8**	16,347 ± 1,983**	54.7 ± 9.3***	131.4 ± 14.2**	5.8 ± 1.1***
Microneedle Patch	456.8 ± 68.9***	2.8 ± 0.6	14,723 ± 1,756*	38.4 ± 6.9***	118.4 ± 12.7*	3.1 ± 0.5***

Values expressed as mean ± SD. Statistical comparison vs conventional suspension: *p<0.05, **p<0.01, ***p<0.001 (one-way ANOVA with Tukey post-hoc test).



Figure 4: Pharmacokinetic Profiles in Rat Model

7.7 Safety and Tolerability Assessment

Injection site examination following intramuscular and subcutaneous administration of novel formulations revealed minimal local reactions. PLGA microsphere injections produced mild transient swelling at injection sites resolving within 3-5 days without intervention, with histopathological examination at 14 days showing minimal inflammatory infiltrate and normal tissue architecture. No abscess formation, necrosis, or persistent granulomas were observed, confirming biocompatibility of the biodegradable polymer system.

ISSN: 2178-7727

Liposomal and solid lipid nanoparticle formulations demonstrated excellent local tolerance with no visible injection site reactions and histology indistinguishable from saline-injected controls. Microneedle application sites showed expected transient erythema lasting 2-4 hours post-application with complete resolution and no signs of infection, irritation, or scarring at 7-day follow-up.

Systemic safety monitoring included weekly body weight measurements, behavioral observations, and hematological parameters assessed at study termination. No significant body weight differences emerged between treatment and control groups (p=0.342), and animals exhibited normal feeding, grooming, and activity patterns throughout the study. Complete blood counts revealed hematocrit values within normal ranges for all groups at 14 days: conventional suspension 47.3 ± 2.1%, PLGA microspheres 45.8 ± 2.4%, liposomes 46.2 ± 1.9%, SLN 45.1 ± 2.3%, microneedles 46.4 ± 2.0%, compared to vehicle control 44.9 ± 2.1% (p=0.689). The absence of polycythemia even with sustained testosterone exposure likely reflects the short study duration insufficient for erythropoietic effects to fully manifest.

Liver and kidney function markers including alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen, and creatinine remained within normal reference ranges across all treatment groups, indicating no hepatotoxic or nephrotoxic effects from testosterone or formulation excipients at the doses studied.

Table 5: Safety and Tolerability Outcomes in Animal Studies

Parameter	Conventional	PLGA Microspheres	Liposomes	SLN	Microneedles	Control	P-value
Injection Site Reaction (score 0-4)	0.67 ± 0.52	1.17 ± 0.41	0.33 ± 0.52	0.50 ± 0.55	0.83 ± 0.41*	0.17 ± 0.41	0.031
Body Weight Change (%)	+3.4 ± 1.8	+3.8 ± 2.1	+3.2 ± 1.6	+3.6 ± 1.9	+3.1 ± 1.7	+3.3 ± 1.5	0.342
Hematocrit (%)	47.3 ± 2.1	45.8 ± 2.4	46.2 ± 1.9	45.1 ± 2.3	46.4 ± 2.0	44.9 ± 2.1	0.689
ALT (U/L)	42.3 ± 8.7	38.9 ± 7.4	41.2 ± 9.1	39.7 ± 8.3	40.8 ± 7.9	39.4 ± 8.2	0.891
Creatinine (mg/dL)	0.62 ± 0.11	0.58 ± 0.09	0.61 ± 0.10	0.59 ± 0.12	0.60 ± 0.11	0.59 ± 0.10	0.923
Mortality	0/6	0/6	0/6	0/6	0/6	0/6	-

Values expressed as mean ± SD (n=6 per group). *p<0.05 vs control; injection site reactions scored as 0=none, 1=minimal erythema, 2=moderate erythema/swelling, 3=severe inflammation, 4=necrosis. Statistical analysis: one-way ANOVA.

DISCUSSION

8.1 Interpretation of Formulation Development Outcomes

This research successfully developed and characterized three distinct testosterone delivery platforms, each demonstrating unique advantages addressing specific limitations of conventional therapy. The systematic optimization approach utilizing quality-by-design principles and response surface methodology enabled identification of critical formulation parameters and their interactions, producing optimized formulations with predictable, reproducible performance characteristics.

The PLGA microsphere platform emerged as the most promising candidate for extended-duration therapy, achieving the primary objective of sustained therapeutic testosterone levels exceeding 11 days from a single administration. The 150.8% relative bioavailability compared to conventional injection represents substantial improvement, likely attributable to several mechanisms. Protection of testosterone within the polymer matrix shields the hormone from rapid enzymatic metabolism during the absorption phase, effectively extending its residence time in circulation. The gradual, controlled release creates a "flip-flop" pharmacokinetic situation

ISSN: 2178-7727

where release rate rather than elimination rate becomes the rate-limiting step, thereby extending apparent half-life to 4.2 days compared to 6.8 hours for unformulated testosterone. Additionally, the particulate nature may facilitate lymphatic uptake, bypassing first-pass hepatic clearance.

The minimal burst release (14.6%) achieved through formulation optimization represents critical advancement over earlier microsphere formulations that often exhibited 30-50% burst due to surface-associated drug. This controlled release profile translates to more stable plasma concentrations without the supraphysiological peaks associated with conventional injections that contribute to adverse effects including mood fluctuations and polycythemia risk. The ability to maintain testosterone within the physiological window (300-1000 ng/mL) for extended duration while avoiding excessive peaks addresses a fundamental clinical challenge in hormone replacement therapy.

Nanotechnology-based carriers, while demonstrating shorter duration than microspheres, offered distinct advantages including enhanced bioavailability through improved solubilization and absorption, potentially enabling dose reduction. The liposomal formulation's 127.3% relative bioavailability reflects effective protection during gastrointestinal passage (if oral delivery were pursued) and enhanced cellular uptake through membrane fusion mechanisms. Solid lipid nanoparticles showed slightly superior sustained release compared to liposomes, attributed to the crystalline lipid matrix providing slower drug diffusion pathways than fluid liposomal bilayers.

The microneedle platform successfully demonstrated proof-of-concept for painless, self-administered testosterone delivery combining transdermal convenience with enhanced bioavailability (118.4%) exceeding conventional transdermal preparations. The rapid initial release upon array dissolution provides quick onset beneficial for symptom relief, while the sustained phase from dermal depot formation extends duration beyond daily gel applications. This formulation particularly addresses patient-reported preferences for non-invasive, discreet delivery avoiding daily application inconvenience and transfer risks associated with gels.

8.2 Theoretical Implications and Mechanistic Insights

The findings contribute to advancing theoretical understanding of testosterone pharmacokinetics and formulation science principles. The documented bioavailability enhancements challenge traditional assumptions that intramuscular injection of lipophilic steroids represents the maximally efficient delivery route. Rather, the data demonstrate that formulation design profoundly influences absorption kinetics, distribution, and elimination patterns even for highly permeable molecules.

The success of biodegradable polymer microspheres validates principles of controlled-release formulation design where polymer degradation kinetics, drug-polymer interactions, and particle size collectively determine release profiles. The strong correlation between formulation parameters and pharmacokinetic outcomes ($R^2 > 0.85$ for multiple relationships) supports the application of quantitative structure-property relationship approaches to hormone delivery system development.

For nanotechnology platforms, the research provides evidence supporting the "enhanced permeation and retention" concept in hormone delivery, demonstrating that nanosize carriers improve bioavailability not only through increased surface area but also through altered biodistribution patterns. The differential performance of liposomes versus solid lipid nanoparticles despite similar size ranges highlights the importance of carrier composition and structure beyond dimensional considerations alone.

8.3 Practical Implications for Clinical Practice

These findings carry significant practical implications for testosterone replacement therapy management. The availability of formulation options with validated pharmacokinetic profiles spanning 3-14 days duration enables personalized therapy selection based on individual patient needs, preferences, and adherence patterns. Patients prioritizing convenience and minimal intervention frequency would benefit most from monthly microsphere injections, while those preferring more frequent dosing with faster reversibility might select

ISSN: 2178-7727

weekly nanoparticle injections or extended-duration microneedle patches.

The demonstrated bioavailability improvements could enable dose reductions of 20-35% compared to conventional formulations while maintaining equivalent testosterone exposure, potentially reducing costs and adverse effect risks. For patients experiencing polycythemia with conventional therapy, the more stable plasma levels achieved by controlled-release formulations may reduce hematocrit elevations by eliminating supraphysiological peak periods that stimulate excessive erythropoiesis.

Healthcare economics also benefit from reduced dosing frequency, with monthly administration potentially decreasing clinic visits, nursing time for injection administration, and patient time costs compared to weekly or biweekly conventional regimens. For self-administered options like microneedles, the elimination of professional administration requirements could further reduce healthcare resource utilization while improving patient autonomy and satisfaction.

8.4 Comparison with Existing Literature

The pharmacokinetic profiles observed in this research align well with published data on similar formulation platforms while extending knowledge in specific areas. The PLGA microsphere performance compares favorably to testosterone undecanoate long-acting injectable approved for clinical use, achieving similar duration (10-14 weeks for undecanoate vs 11.4 days for our formulation in rat models, which translates to approximately 10-12 weeks in humans through allometric scaling). However, the more controlled release kinetics with minimal burst represent advancement over some commercial products that exhibit greater peak-to-trough fluctuation.

Published microneedle research for testosterone has been limited, with most studies reporting only in vitro characterization without pharmacokinetic validation. This research extends the evidence base by demonstrating that dissolving microneedle delivery achieves superior bioavailability and duration compared to conventional gels in animal models, supporting clinical development potential. The 3.1-day therapeutic duration in rats suggests 7-10 day potential in humans, enabling twice-weekly self-administration as an alternative to daily gels.

The nanotechnology findings corroborate trends reported in recent literature demonstrating 20-40% bioavailability improvements with lipid nanocarriers for lipophilic drugs. Our specific values for testosterone fall within this range, with solid lipid nanoparticles slightly outperforming liposomes consistent with comparative studies in other hormones attributing superior performance to crystalline lipid matrix stability.

Some divergence exists regarding stability profiles, with our data showing more favorable stability for PLGA microspheres (97.3% retention at 6 months) compared to some published reports indicating 85-90% retention. This likely reflects the optimized polymer selection, controlled manufacturing conditions, and lyophilized storage approach employed in this research, highlighting the importance of process control for stability outcomes.

8.5 Limitations and Alternative Interpretations

Several limitations warrant acknowledgment and consideration of alternative interpretations. The primary limitation involves translation from rodent pharmacokinetics to human predictions. While allometric scaling provides reasonable estimates, interspecies differences in testosterone metabolism, tissue distribution, and binding protein concentrations may produce different pharmacokinetic profiles in humans than observed in rats. The 11.4-day duration in rats likely translates to 4-12 weeks in humans based on metabolic rate differences, but clinical trials will be required to establish actual human pharmacokinetics definitively.

The relatively small sample size (n=6 per group) provides adequate statistical power for detecting large differences but may miss subtle variations or rare adverse events. Larger studies with extended duration would better characterize safety profiles, particularly regarding potential concerns like cardiovascular effects or

ISSN: 2178-7727

prostate stimulation requiring longer observation periods than the 14-day study conducted here.

Alternative explanations for observed bioavailability improvements deserve consideration. While attributed primarily to formulation-mediated protection and controlled release, individual animal variability in metabolism, injection technique variations, or sampling timing inaccuracies could contribute to measured differences. The use of standardized analytical methods, randomization, and blinded sample analysis mitigate but cannot completely eliminate these potential confounders.

The stability data, while encouraging, represent accelerated conditions that may not perfectly predict long-term real-world storage outcomes. Some degradation pathways may not accelerate proportionally with temperature increases, and photodegradation or other environmental factors not captured in ICH stability protocols could emerge during commercial distribution.

8.6 Regulatory and Translational Considerations

Advancing these formulations from laboratory research to clinical application requires navigating complex regulatory pathways. For PLGA microsphere formulations, the use of FDA-approved PLGA polymers and established manufacturing techniques provides regulatory advantages, potentially enabling abbreviated development pathways compared to entirely novel excipients. However, the depot formulation classification necessitates comprehensive pharmacokinetic characterization in humans demonstrating acceptable release characteristics and bioequivalence to approved products or, alternatively, independent clinical efficacy and safety demonstration.

Nanotechnology-based formulations face heightened regulatory scrutiny due to unique properties of nanoscale materials potentially altering biological interactions. FDA guidance on nanotechnology products requires extensive characterization of critical quality attributes including particle size distribution, surface properties, morphology, and demonstration that manufacturing processes consistently produce materials within specifications. The relatively straightforward composition of lipid nanocarriers using approved ingredients provides advantages over more complex nanomaterials.

Microneedle devices face dual regulation as both drug and device combination products, requiring demonstration of both pharmaceutical quality (drug content, uniformity, stability) and device performance (penetration capability, reproducible delivery). Recent FDA guidance on microneedle products provides clearer pathways, with several microneedle systems gaining approval for other indications establishing regulatory precedents applicable to testosterone delivery.

Manufacturing scalability represents another critical translational consideration. The laboratory-scale methods employed in this research require adaptation to industrial manufacturing scales while maintaining product quality and consistency. PLGA microsphere manufacturing is well-established commercially, but achieving consistent particle size distribution, drug loading, and release characteristics at large scale requires sophisticated process control. Microneedle array fabrication technology has advanced significantly with roll-to-roll manufacturing approaches enabling mass production, though drug-loaded arrays require careful environmental control to prevent premature dissolution or degradation.

8.7 Future Research Directions

This research establishes foundations for multiple future investigation directions. Most immediately, dose-ranging studies in animal models would optimize testosterone loading to achieve target human-equivalent dosing while maintaining favorable release profiles. Subsequent good laboratory practice toxicology studies over 3-6 months would provide comprehensive safety data supporting regulatory submissions and clinical trial applications.

Comparative human pharmacokinetic studies represent the critical next step, initially in healthy volunteers to establish safety and basic pharmacokinetics, followed by phase II efficacy and safety studies in hypogonadal

ISSN: 2178-7727

men. These trials should employ validated patient-reported outcome measures assessing symptom relief, quality of life, treatment satisfaction, and adherence compared to conventional therapies. Long-term safety monitoring over 12-24 months would assess cardiovascular outcomes, prostate effects, and other potential adverse events.

Additional formulation refinement could explore combination approaches, such as microneedle arrays loaded with nanoparticulate testosterone providing both rapid onset and extended duration, or microspheres with programmed pulsatile release mimicking circadian testosterone rhythms. Investigation of alternative biodegradable polymers with varying degradation kinetics could enable customized release durations matching individual patient preferences from weekly to quarterly dosing intervals.

The mechanisms underlying observed bioavailability improvements deserve deeper investigation through metabolomic studies, tissue distribution analyses, and cellular uptake pathway characterization. Understanding whether enhanced bioavailability primarily reflects reduced metabolism, altered distribution, lymphatic uptake, or other mechanisms would enable further formulation optimization targeting specific pathways.

Patient preference and adherence studies comparing these novel formulations to conventional therapies in real-world settings would provide valuable evidence regarding practical clinical utility. Such research should include diverse patient populations regarding age, ethnicity, comorbidities, and socioeconomic status to ensure findings generalize broadly and identify potential disparities in treatment access or outcomes.

CONCLUSION

This comprehensive research successfully developed and validated novel testosterone delivery systems addressing critical limitations of conventional replacement therapy for male hypogonadism. Through systematic formulation development, rigorous characterization, and in vivo pharmacokinetic evaluation, the study demonstrated that innovative delivery platforms including biodegradable polymer microspheres, lipid-based nanocarriers, and dissolving microneedle arrays offer substantial advantages over existing therapies regarding sustained release, enhanced bioavailability, and improved administration convenience.

The optimized PLGA microsphere formulation achieved the primary research objective, delivering testosterone with 150.8% relative bioavailability and maintaining therapeutic plasma concentrations for 11.4 days in animal models, translating to potential monthly dosing in humans. This extended duration combined with stable plasma levels avoiding supraphysiological peaks addresses the fundamental challenge of fluctuating hormone levels inherent to conventional short-acting injections. The minimal burst release and favorable safety profile demonstrated through comprehensive toxicological assessment support advancement to clinical development phases.

Nanotechnology-based carriers including liposomes and solid lipid nanoparticles similarly demonstrated enhanced bioavailability (127-131%) with moderate duration extension, offering intermediate options for patients preferring more frequent dosing than monthly injections but seeking improvements over daily transdermal applications. The successful application of quality-by-design optimization principles yielded formulations with reproducible, predictable performance characteristics essential for pharmaceutical development.

The microneedle platform validated proof-of-concept for painless, self-administered testosterone delivery combining transdermal convenience with superior bioavailability (118.4%) and extended duration (3.1 days in rats, potentially 7-10 days in humans) compared to conventional gels. This formulation addresses patient-reported preferences for non-invasive delivery while eliminating transfer risks and daily application burdens that compromise adherence with current transdermal options.

Key Contributions to Knowledge:

This research makes several significant contributions advancing the field. First, it provides the most

ISSN: 2178-7727

comprehensive comparative evaluation of multiple testosterone delivery platforms under standardized conditions reported to date, enabling evidence-based formulation selection for specific clinical scenarios. Second, the systematic optimization employing design of experiments approaches establishes relationships between formulation variables and performance outcomes, creating predictive models guiding future development. Third, the rigorous progression from pre-formulation through in vivo validation establishes a translational research framework applicable to other hormone and peptide delivery challenges.

Clinical and Public Health Implications:
The practical impact extends directly to patient care and public health outcomes. By developing formulations that reduce dosing frequency, minimize adverse effects, and offer diverse administration options matching individual preferences, this work addresses the primary factors contributing to poor adherence that affects approximately 50% of hypogonadal men within one year of treatment initiation. Improved adherence translates to better symptom control, enhanced quality of life, reduced complications from untreated hypogonadism, and potentially lower overall healthcare costs through decreased hospitalization and emergency care for preventable complications.

The availability of self-administered options like microneedle patches could expand treatment access to underserved populations facing barriers accessing frequent clinic visits for injections, including rural residents, those with limited healthcare access, and patients with mobility limitations. The potential for dose reduction through enhanced bioavailability could make therapy more affordable, addressing economic barriers to treatment access.

Regulatory and Commercial Pathway:
The formulations developed in this research utilize approved excipients and established manufacturing approaches, providing clear regulatory pathways to clinical application. The next critical steps involve good manufacturing practice production for clinical trial materials, comprehensive toxicology studies meeting regulatory requirements, and phase I-III clinical trials establishing safety and efficacy in human subjects. The strong preclinical foundation established through this research positions these formulations favorably for successful clinical translation.

Achievement of Stated Objectives:
Each research objective stated at the study outset was successfully achieved. The primary objective of developing formulations with superior pharmacokinetic profiles and enhanced bioavailability was demonstrated through multiple platforms. Secondary objectives including systematic pre-formulation characterization, multi-platform formulation development, comprehensive in vitro evaluation, in vivo pharmacokinetic validation, and safety assessment were all completed with rigorous methodologies and meaningful outcomes.

Final Perspective:
Male hypogonadism represents a prevalent, impactful condition affecting millions of men globally, yet current treatment options remain suboptimal as evidenced by poor adherence rates and patient dissatisfaction. This research demonstrates that pharmaceutical innovation applying modern drug delivery technologies can meaningfully advance therapy by addressing root causes of treatment failure rather than merely offering incremental improvements. The novel formulations developed and validated here represent tangible steps toward the goal of personalized testosterone replacement therapy where patients and clinicians can select formulation approaches optimally suited to individual needs, preferences, and circumstances.

The path from laboratory innovation to widespread clinical implementation requires sustained effort through regulatory processes, clinical validation, manufacturing scale-up, and healthcare system integration. However, the scientific and technical foundations established through this research provide solid ground for that journey. By demonstrating feasibility, safety, and superior performance of novel delivery systems, this work opens new possibilities for improving the lives of hypogonadal men through better, more patient-centered hormone

ISSN: 2178-7727

replacement therapy.

Ultimately, the measure of this research's success will not be in publications or patents but in improved outcomes for patients struggling with testosterone deficiency. If the formulations developed here can help men maintain treatment adherence, experience better symptom control, and enjoy improved quality of life, then the scientific effort invested in their development will have achieved its most important objective—translating pharmaceutical science into tangible human benefit.

REFERENCES

1. Bhasin, S., Brito, J.P., Cunningham, G.R., Hayes, F.J., Hodis, H.N., Matsumoto, A.M., Snyder, P.J., Swerdloff, R.S. and Watts, N.B. (2018) 'Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline', *Journal of Clinical Endocrinology & Metabolism*, 103(5), pp. 1715-1744. Available at: https://doi.org/10.1210/jc.2018-00229
2. Corona, G., Goulis, D.G., Huhtaniemi, I., Zitzmann, M., Toppari, J., Forti, G., Vanderschueren, D. and Wu, F.C. (2019) 'European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males', *Andrology*, 8(5), pp. 970-987. Available at: https://doi.org/10.1111/andr.12770
3. Kaminetsky, J., Hemani, M.L. and Farrer, J. (2015) 'Pharmacokinetic profiles of subcutaneous testosterone pellets (Testopel®) over 6 months', *Clinical Endocrinology*, 82(3), pp. 415-422.
4. Kaur, R., Sharma, N., Gupta, M. and Dua, J.S. (2018) 'Development and optimization of testosterone loaded solid lipid nanoparticles using response surface methodology', *Journal of Drug Delivery Science and Technology*, 44, pp. 408-417.
5. Nassar, G.N. and Leslie, S.W. (2023) 'Physiology, testosterone', in *StatPearls*. Treasure Island, FL: StatPearls Publishing. Available at: https://www.ncbi.nlm.nih.gov/books/NBK526128/
6. Nguyen, H.X., Bozorg, B.D., Kim, Y., Wieber, A., Birk, G., Luong, D. and Banga, A.K. (2020) 'Poly (lactic-co-glycolic acid) microspheres for controlled delivery of testosterone', *Journal of Drug Delivery Science and Technology*, 57, 101639.
7. Nieschlag, E. and Vorona, E. (2015) 'Mechanisms in endocrinology: medical consequences of doping with anabolic androgenic steroids', *European Journal of Endocrinology*, 173(2), pp. R47-R58.
8. Pastuszak, A.W. (2019) 'Current diagnosis and management of testosterone deficiency', *Current Opinion in Urology*, 29(6), pp. 578-585. Available at: https://doi.org/10.1097/MOU.0000000000000681
9. Pastuszak, A.W., Pearlman, A.M., Lai, W.S., Godoy, G., Sathyamoorthy, K., Liu, J.S. and Lipshultz, L.I. (2016) 'Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy', *Journal of Urology*, 195(3), pp. 639-644.
10. Salonia, A., Rastrelli, G., Hackett, G., Seminara, S.B., Huhtaniemi, I.T., Rey, R.A., Hellstrom, W.J., Palmert, M.R., Ferlin, A., Giwercman, A. and Maggi, M. (2021) 'Paediatric and adult-onset male hypogonadism', *Nature Reviews Disease Primers*, 7(1), pp. 1-21. Available at: https://doi.org/10.1038/s41572-021-00297-9
11. Schubert, M. and Jockenhövel, F. (2020) 'Late-onset hypogonadism in the aging male: pathogenesis, diagnosis and treatment', *Deutsches Ärzteblatt International*, 117(35-36), pp. 583-590.
12. Sharma, S., Saeed, A., Johnson, C., Gadegaard, N. and Clokie, S. (2021) 'Rapid, low-cost fabrication of transient electronic devices using 3D printed templates', *Microsystems & Nanoengineering*, 7(1), pp. 1-11.
13. Snyder, P.J., Bhasin, S., Cunningham, G.R., Matsumoto, A.M., Stephens-Shields, A.J., Cauley, J.A., Gill, T.M., Barrett-Connor, E., Swerdloff, R.S., Wang, C. and Ensrud, K.E. (2016) 'Effects of testosterone treatment in older men', *New England Journal of Medicine*, 374(7), pp. 611-624. Available at: https://doi.org/10.1056/NEJMoa1506119